Diabetes

Subterms

    More stories

    • 163 Shares129 Views

      in Elections

      6 Reasons That It’s Hard to Get Your Wegovy and Other Weight-Loss Prescriptions

      by

      An array of obstacles make it difficult for patients to obtain Wegovy or Zepbound. Finding Wegovy is “like winning the lottery,” one nurse practitioner said.Talk to people who have tried to get one of the wildly popular weight-loss drugs, like Wegovy, and they’ll probably have a story about the hoops they had to jump through to get their medication — if they could get it at all.Emily Weaver, a nurse practitioner in Cary, N.C., said she told her patients that finding Wegovy was “like winning the lottery.”Here are six reasons why.1. Demand is very high.Fueled in part by TikTok videos and celebrity testimonials, people are increasingly seeking prescriptions for appetite-suppressing medications. The drugs in this class have long been used to treat diabetes but more recently have been recognized for their extraordinary ability to help patients lose weight. The medications are injected weekly and have sticker prices as high as $16,000 a year.About 3.8 million people in the United States — four times the number two years ago — are now taking the most popular weight-loss drugs, according to the IQVIA Institute for Human Data Science, an industry data provider. Some of these prescriptions are for diabetes. The medicines are Novo Nordisk’s Ozempic and Wegovy (the same drug sold under different brand names), and Eli Lilly’s Mounjaro and Zepbound (also the same drug).We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    • 113 Shares159 Views

      in Elections

      DeSantis Bows Out, and So Does This Winter Freeze

      by

      The New York Times Audio app is home to journalism and storytelling, and provides news, depth and serendipity. If you haven’t already, download it here — available to Times news subscribers on iOS — and sign up for our weekly newsletter.The Headlines brings you the biggest stories of the day from the Times journalists who are covering them, all in about five minutes.The Florida governor, who once appeared to be Donald Trump’s most daunting challenger, ran a costly and turbulent campaign that failed to catch on with Republican voters.Nicole Craine for The New York TimesOn Today’s Episode:Ron DeSantis Ends Campaign for President, by Nicholas Nehamas, Maggie Haberman, Jonathan Swan and Shane GoldmacherAs U.S. and Militias Engage, White House Worries About a Tipping Point, by Peter BakerAt Least 72 Deaths in U.S. Are Connected to Severe Winter Weather, by Jacey Fortin and Colbi EdmondsF.A.A. Tells Airlines to Check Panels on a Second Boeing Plane, by Mark WalkerDiabetes Is Fueling an Amputation Crisis for Men in San Antonio, by Edgar SandovalNicholas Nehamas and Jessica Metzger and More

    • 75 Shares149 Views

      in Elections

      An Anti-Obesity Drug and Cultural Stigmas

      by

      More from our inbox:Seeking More Insight Into Republican VotersScandal at Liberty UniversityFree Analysis? Alice Rosati/Trunk ArchiveTo the Editor:Re “Ozempic Can’t Fix What Our Culture Has Broken,” by Tressie McMillan Cottom (column, Oct. 15):By “broken” in the headline, the column implies that we still perpetuate a cultural bias against obese people.Yes, we do stigmatize fat people. I’m fat. What’s also broken, though, is our habit of blaming society for failing to accept us, and medical institutions for failing to fix us, before we take an honest look at our own choices contributing to becoming unhealthy in the first place.Clearly obesity is an epidemic with complex environmental, economic and genetic factors. But for most, physical activity and healthy eating are still nature’s best prevention and remedy. Unlike Ozempic, they’re not a sexy quick fix. They’re work.Maybe healthy eating and activity are just too simple. But viewing ourselves first as victims of unfair systems is also not the answer.Society will always judge. Institutions will always be profit-driven. Blaming is easy. Honest self-assessment and changing habits are hard.Leslie DunnCarmel, Calif.To the Editor:Tressie McMillan Cottom’s fine column covers almost all the issues that I, as a slightly overweight but not obese woman, have with the new weight-loss drugs.But one issue needs to be addressed: What will we think about and how will we treat people (women) who choose not to take this drug, for whatever reason? Maybe it’s because it’s too expensive; maybe because it’s a commitment to a lifetime of taking the drug; maybe it’s just, amazingly, because they are comfortable in their rounded, plush bodies, and don’t desire to change them. Will they face even more opprobrium for that choice than they already do?I’ve spent the last 66 years (and counting) being told that my body isn’t “right,” by doctors, family and society. I’ve just finally come to terms with the fact that I’m stuck in it, and I’m lucky to be able to wake up every morning and get out of bed. Isn’t that enough?Naomi Weisberg SiegelPittsburghTo the Editor:While I agree with the author on many points, one point she didn’t address effectively is that Ozempic and other weight-loss drugs help cover up a main culprit that is causing our obesity: the U.S. food industry and “ultraprocessed foods.”Up until about the 1980s the U.S. didn’t have such a serious obesity problem. Then sugar began being added to everything, along with other things not found in any garden or kitchen.Dr. McMillan Cottom points out that people can be obese and be healthy, but that is not true of most obese people. Ozempic was created because of rampant diabetes in the U.S., the risk of which is increased by eating ultraprocessed foods.Our food industry is killing us with slow deaths from chronic diseases.Deborah JerardMontpelier, Vt.The writer is a pediatrician.Seeking More Insight Into Republican VotersWhy These 11 Republican Voters Like Trump But Might Bail on HimThe group discusses what it would take for a candidate other than Trump to win their vote.To the Editor:Re “Could These Republican Voters Abandon Trump?” (“America in Focus” series, Opinion, Oct. 22):This piece was disturbing but unenlightening about why voters support Donald Trump.Focus groups are supposed to probe for deeper understanding of participants’ views, yet your moderator accepted answers without delving into how participants reached those views.For example, when Cristian said about Donald Trump that “he does get things done,” the moderator could have asked for specifics. It would have been an interesting answer because Mr. Trump actually got very little done.The most glaring omission was Mr. Trump’s false claims of a stolen 2020 election. Do participants agree with Mr. Trump? Where do they get their news? Does this issue even matter to them?We have known for months that Mr. Trump maintains strong voter support. We might have gotten some insight into why had the moderators asked more clarifying questions.Ann LaubachAustin, TexasTo the Editor:First, I will applaud both Kristen Soltis Anderson for her skilled questions and moderation, as well as Patrick Healy and the Times Opinion team for sticking with your amazing series, most recently “Could These Republican Voters Abandon Trump?” Fascinating stuff.But just like the infamous CNN town hall with Donald Trump, it leaves an urgent set of questions. Mainly these:1. What about the criminal cases against Mr. Trump?2. What about climate change and the green agenda?Without understanding in depth these 11 Republicans on these topics, I just don’t see how I can evaluate. Of course, I recognize that these individuals have most likely completely dismissed these entire areas of thought. Nonetheless, to understand the situation in my country, I need to see what rationales they are using to do that.George OdellNewburyport, Mass.Scandal at Liberty University Julia Rendleman for The New York TimesTo the Editor:Re “The Worst Scandal in American Higher Education,” by David French (column, Oct. 23):Thank you to Mr. French for bringing the truly appalling behavior of Liberty “University” officials to our attention. Yet while he reports that the $37.5 million fine Liberty might face would be “unprecedented,” I can’t help but wonder why the Department of Education wouldn’t strip Liberty of its accreditation altogether, making it ineligible to receive federal money.Such a move is long overdue, and not just because Liberty has lied about campus crime and pressured victims of sexual assault to stay quiet. Liberty, and a host of other Christian institutions, are not colleges in the critical sense. These are places where answers precede questions, where intellectual exploration is hemmed in by theological dogma, and where basic tenets of academic freedom are treated as optional.Why should taxpayers be funding education at such places at all?Steven ConnYellow Springs, OhioThe writer is a professor of history at Miami University.Free Analysis?James AlbonTo the Editor:“How Do You Charge a Friend for a Professional Favor?” (Business, nytimes.com, Oct. 21): Another favor-asking situation that commonly occurs is asking physicians, be they friends or a recent acquaintance at a social event, for free medical opinions or even advice. The many ways of handling those situations would warrant an entire New York Times article.There is another common experience that occurs when one is introduced to someone as a psychiatrist, psychoanalyst or therapist in nonprofessional settings.Such introductions often evoke the question, “Are you analyzing me?” To which I almost always respond, “Not if you’re not paying me.” And we move on.Jack DrescherNew YorkThe writer, a psychiatrist and psychoanalyst, is past president of the Group for Advancement of Psychiatry. More

    • 138 Shares189 Views

      in US Politics

      Drugmaker Eli Lilly says it will cut insulin prices by 70%

      by

      Drugmaker Eli Lilly says it will cut insulin prices by 70%Move comes amid criticism of healthcare companies over rising costs of insulin, as CEO says cuts ‘should be the new standard’Eli Lilly will cut list prices by 70% for its most commonly prescribed forms of insulin, Humalog and Humulin, beginning from the fourth quarter of this year, the drugmaker said on Wednesday.The move comes amid criticism of healthcare companies by US lawmakers over rising costs of insulin, with Joe Biden’s signature Inflation Reduction Act including a $35 cap on insulin for those enrolled in Medicare health insurance plans.More than a million Americans ration insulin due to high costsRead more“While we could wait for Congress to act or the healthcare system in general to apply that standard, we’re just applying it ourselves,” the company’s chief executive, Dave Ricks, told CNN in an interview.The drugmaker will also lower the price of its non-branded insulin injection Lispro to $25 a vial and expand its Insulin Value Program, under which the $35 cap will apply to about 85% of US pharmacies.Rick said patients using other pharmacies that do not participate in the program can get a rebate through the drugmaker’s website.He said the price cuts “should be the new standard in America” and called on other companies and stakeholders “to meet up at this point”.“Insulin has become such a pivotal issue because of affordability,” Rick said.About 8.4 million of the 37 million people in the United States with diabetes use insulin, according to the American Diabetes Association.Eli Lilly, along with Sanofi and Novo Nordisk, makes up 90% of the US market for insulin.Drugmakers had previously priced insulin at more than $275 a vial, representing a 1,200% increase in price over the past 20 years, according to the advocacy group Insulin Initiative.TopicsPharmaceuticals industryDiabetesUS politicsnewsReuse this content More

    • 113 Shares99 Views

      in Elections

      A Resonant Topic in Georgia’s Senate Runoff: Insulin Prices

      by

      The cost of insulin is nowhere near as contentious as just about everything else raised in the runoff, but in a state with a high diabetes rate, it has proved a powerful issue.MACON, Ga. — The runoff election for Senate in Georgia has not lacked for drama, with a fresh round of attack ads, a fevered get-out-the-vote effort and both sides casting the outcome as pivotal for the nation’s future even though control of the chamber is no longer at stake.But one campaign issue relevant to many voters has little to do with the highly partisan horse race. Rather, it involves one of the most common chronic diseases in America, diabetes, and the soaring cost of the medicine used to treat it, insulin. In both the general and runoff campaigns, Senator Raphael Warnock, the Democratic incumbent, has made much of his efforts in Congress to cap the price of insulin at $35 a month, talking them up in ads, debates and speeches.“It has resonated with just about everyone,” said Dr. Kris Ellis, a physician who also owns the Bearfoot Tavern in Macon, where Mr. Warnock made a recent campaign stop. “If you don’t have diabetes, you know someone with diabetes.”He was describing an unsettling reality in Georgia, as in much of the South, where diabetes rates are staggeringly high and the escalating cost of insulin over the years has led to painful choices and, for some, catastrophic consequences.“I have someone in my family with diabetes who couldn’t afford insulin,” Tony Brown, 57, said on a recent afternoon as he walked into a building in downtown Macon where he works as an engineer. For that reason, he said, he would turn out one more time to vote for Mr. Warnock in Tuesday’s runoff.As campaign issues go, the price of insulin is nowhere near as contentious as just about everything else raised in the four-week runoff between Mr. Warnock and Herschel Walker, the former football star who is his Republican challenger. Even so, interviews with Dr. Ellis and a number of other voters suggested it had broken through the noise of the high-decibel contest, which Georgia requires because neither candidate won a majority of the vote in the general election.“I have someone in my family with diabetes who couldn’t afford insulin,” Mr. Brown said.Nicole Craine for The New York TimesMr. Warnock has focused on lowering insulin prices since arriving in the Senate nearly two years ago, motivated in part by hundreds of letters that have poured into his office, pleading with him to do something. He has also described seeing the ravaging impacts of diabetes, including losing limbs and eyesight, on congregants at Ebenezer Baptist Church in Atlanta, where he is the senior pastor.“This isn’t an ideological matter, it’s a practical one — and it has broad support across the political spectrum,” Mr. Warnock wrote last spring in an opinion essay published in The Atlanta Journal-Constitution.Earlier this year, he introduced legislation that would require both Medicare and private insurers to cap out-of-pocket costs for insulin at $35 a month. The average out-of-pocket cost per prescription reached $54 in 2020, according to an analysis by the Kaiser Family Foundation, which also found that many patients pay significantly more for diabetes care.What to Know About Georgia’s Senate RunoffCard 1 of 6Another runoff in Georgia. More

    • 75 Shares189 Views

      in Elections

      The Water Crisis in the Southwest

      by

      More from our inbox:Should Liz Cheney Run for President?Jerrold Nadler’s Feminist CredentialsLiving With Diabetes John Locher/Associated PressTo the Editor:Re “The Coming Crisis on the Colorado River,” by Daniel Rothberg (Sunday Opinion, Aug. 7):The difference between 33 degrees Fahrenheit and 31 degrees Fahrenheit is the difference between rain and snow. The two-degree increase in ambient temperature in many parts of the Southwest, already recorded, has had a critical effect on the dwindling water levels of the Colorado River.The spigot that turns on water for Lake Mead and Lake Powell reservoirs resides high in the mountains of Colorado where dense snowpack builds up during the winter and melts slowly during the summer.Snowmelt runoff, unlike rainfall that becomes widely dispersed, is channeled into creeks and small streams that eventually combine and funnel into the Colorado River. The snowpack is disappearing.Ten years ago I was at Lake Mead’s now-disappeared Overton Beach Marina and read a sign on a palm tree that said, “Boat Slips Available.” Behind it was a vast landscape of dry and cracked lake bed. The “coming crisis on the Colorado River” has been arriving for some time now.For decades people in the urban Southwest have been living off federal money for subsidized water, with dams, aqueducts and pumping systems watering hundreds of golf courses, a swimming pool for every house and citrus groves in the desert.When the water level of Lake Mead reaches 1,042 feet above sea level, as it did recently, this false idea of a “desert miracle” confronts the true reality of a “dead pool” and the meaning of climate change.Judith NiesCambridge, Mass.The writer is the author of “Unreal City: Las Vegas, Black Mesa and the Fate of the West.”To the Editor:The West is drying and the East is flooding: Lake Mead, the vital sign of the Colorado River, has fallen to historic lows, and Kentucky has the opposite problem, overwhelmed by floodwaters.At a time when the country is already divided in enough ways, I hope that water can be a theme we can all rally around. Whether too much or too little, water touches us all.Certainly, resolving the Colorado River crisis — with its roots now gnarled in agriculture, urban growth, economics, politics and climate change — is a massive undertaking that will not happen in a day or even a decade. It requires individuals as well as institutions.A small action, whether to conserve water at home or to support a policy at the ballot box, shows commitment. To those of us who live in the West, it’s more than just a drop in the bucket. It’s good leadership, and it’s good stewardship.Robert B. SowbyProvo, UtahThe writer is a water resources engineer and a professor at Brigham Young University.Should Liz Cheney Run for President?Representative Liz Cheney spoke to her supporters on Tuesday night in Jackson, Wyo., and on Wednesday announced her new anti-Trump political organization.Kim Raff for The New York TimesTo the Editor:Re “Liz Cheney Says She’s ‘Thinking’ About Running for President in 2024” (news article, nytimes.com, Aug. 17):The heroic stance that soon-to-be-former Representative Liz Cheney has taken will go down in history as a true “profile in courage,” but her trajectory should not include a run for president. More

    • 125 Shares129 Views

      in US Politics

      Republicans vote against insulin bill as price soars, dismaying diabetics

      by

      Republicans vote against insulin bill as price soars, dismaying diabeticsCost of the life-saving drug will remain many times higher than in other affluent countries after Republicans defeated the measure During the Covid-19 pandemic, Erin Connelly had to ration insulin while transitioning to a different health insurance plan. When Connelly heard the Biden administration was planning to cap the price of the life-saving drug, she was delighted. She was soon to be disappointed.The prices of insulin has soared in the US in recent decades and is more than eight times higher in the US than in 32 comparable, high-income nations, according to a Rand Corporation study.With an average list price of $98.70 per unit in the US, compared with $7.52 in the UK, US insulin sales account for nearly half the pharmaceutical industry’s insulin revenue, though the US makes up only about 15% of the global market.Many diabetics require several vials of insulin a month, in addition to the costs of medical supplies and monitoring equipment. A 2022 study by CharityRx found 79% of Americans with diabetes or who care for someone with diabetes reported taking on credit card debt to pay for insulin, with an average debt of $9,000. One in four Americans have reported rationing insulin due to the high costs, which can be fatal.As part of the Inflation Reduction Act passed in the Senate this week, the Biden administration proposed a $35 monthly cap on the cost of insulin in the private market. But the proposal was blocked by Republicans. Connelly, a type 1 diabetic from Illinois who was diagnosed at the age of 33, said she was “devastated”.“I believe the profit margin on my life must be really good, otherwise, we would be a bigger focus and a bigger part of these healthcare negotiations,” she said. “People are actually dying from this and it’s beyond price gouging. They’re holding us for ransom.“As we see things like Covid and different viruses come in and attack bodies in ways that we don’t understand, we’re seeing higher rates of people with type 1 diabetes later in life like I was, so this should be a primary concern for public health officials,” she said.Thanks to budgetary rules the proposal needed 60 votes to pass in the Senate. It received 57, with all Democrats and seven Republicans voting in favor of the proposal, though the Senate parliamentarian did allow the cap on co-pays for Medicare, the government health insurance program for those 65 and older.The vote incited criticism against Republicans from diabetes advocates who have been pushing for legislation to cap the cost of insulin in the US.But even a cap on private insurance co-pays wouldn’t have affected the real price of insulin in the US. The proposal would merely have limited the co-pay for the price of insulin to $35 for those with private insurance, with insurance expected to cover the difference. It would also probably have resulted in increases for insurance premiums. Those without insurance would still have been expected to pay exorbitant prices for insulin.“The co-pay caps aren’t price caps. All they effectively do is if you have insurance or Medicare, the $35 is your maximum co-pay,” said Laura Marston, co-founder of the advocacy group the Insulin Initiative and a type one diabetic. “That doesn’t change the underlying price of what someone without insurance pays for insulin, which in and of itself is concerning and scary from a patient’s point of view because I know first-hand how hard it can be as a type 1 diabetic in this country to get and keep health insurance.”Marston pointed out that pharmaceutical companies such as Eli Lilly have supported the insurance co-pay caps. While she was disappointed by the failure of the co-pay cap proposal, even if she feels it fell short of a real solution to the problem, she is also concerned about the lack of political will to take on the pharmaceutical industry and cap the actual prices of insulin.More than 100,000 Americans died in 2021 from diabetes. More than 30 million Americans are diagnosed with type 1 or type 2 diabetes and over 7 million require daily insulin – all type 1 diabetics and many type 2 diabetics.For now diabetics and their families who were hoping for some relief are back where they started – paying exorbitant fees for a life-saving medicine.“We’ve been trying to no avail to get an actual insulin price cap introduced that would say to insulin makers, you cannot charge more than say, we’ll just say $20 a vial, or basically you cannot charge more than what you charge in other countries for insulin. And it felt like it fell on deaf ears as soon as this co-pay cap was introduced,” said Marston. “I don’t know why they introduced something seemingly half hearted, not really designed to be a solution to the problem.”TopicsDiabetesPharmaceuticals industryBiden administrationUS politicsnewsReuse this content More